Canaccord Genuity Reiterates a 'Buy' on DexCom (DXCM); Solid Q4 & Conservative Guidance
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $92.34 --0%
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 57
Rating Summary:
32 Buy, 7 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 6 | Down: 6 | New: 57
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on DexCom (NASDAQ: DXCM) price target raised from $11.00 to $11.50.
Analyst, William J. Plovanic, said, "We reiterate our rating following strong Q4/11 revenue results (in-line with preliminary numbers). Revenue guidance was reaffirmed, but we believe it is conservative. Lastly, the completion (and hopeful submission) of the Gen4 IDE trial during the Q1/12 is encouraging as a new product cycle is needed to drive major growth and improve profitability in 2013 and beyond."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $11.19 yesterday.
Analyst, William J. Plovanic, said, "We reiterate our rating following strong Q4/11 revenue results (in-line with preliminary numbers). Revenue guidance was reaffirmed, but we believe it is conservative. Lastly, the completion (and hopeful submission) of the Gen4 IDE trial during the Q1/12 is encouraging as a new product cycle is needed to drive major growth and improve profitability in 2013 and beyond."
For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.
Shares of DexCom closed at $11.19 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) PT Lowered to $6 at Stephens
- CTG Duty Free Corp Ltd (601888:CH) PT Lowered to RMB64 at Macquarie
- Guggenheim Starts Jersey Mike's Subs (JMKE) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
